Safety, Feasibility, and Tolerability of Sulforaphane in Children With Chronic Kidney Disease

• Status: Not yet recruiting
• Trial end date: 2023-08-31
• Target enrollment: 0
• Participant gender: All

Summary

This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Rochester
• Collaborator: Renal Research Institute
• Treatments: Sulforaphane

Criteria

Inclusion Criteria:

• diagnosis of chronic of kidney disease

• have eGFR 20-59 mL/min/1.73m2 at the time of enrollment

• parents must be able to provide consent

Exclusion Criteria:

• weight <30 kg

• cancer or HIV diagnosis

• history of solid organ transplantation (including kidney transplant)

• structural heart disease

• currently pregnant or plan to become pregnant

• life expectancy is less than one year

• Patients will also be excluded if they are currently taking anticoagulants, immunosuppression, or chemotherapeutics